Clinical Trials

Clinical Trial Detail

Return to search results.

SPECT/CT in Measuring Lung Function in Patients With Lung Cancer Undergoing Radiation Therapy

Complete title: Pulmonary Functional Imaging for Radiation Treatment Planning for Lung Cancer

Research Study Number       8180
    
Principal Investigator       Jing Zeng
    
Phase       Pilot

Look up trial at NIH

Research Study Description

This pilot clinical trial studies single photon emission computed tomography (SPECT)/computed tomography (CT) in measuring lung function in patients with lung cancer undergoing radiation therapy. Diagnostic procedures that measure lung function may help doctors find healthy lung tissue and allow them to plan better treatment.

Eligibility Criteria (must meet the following to participate in this study)

Ages Eligible for Study: 19 Years and older

Genders Eligible for Study: Both

- Lung cancer patients receiving radiation treatment to the thorax to at least 45 Gy; both non-small cell and small cell patients are eligible; patient must have pathologic confirmation of diagnosis, or have an enlarging lung mass on at least two scans spaced 3 months apart, and fludeoxyglucose F-18 (FDG) avidity on positron emission tomography (PET) scan

- All stages of lung cancer are eligible, but patients must be planned for at least 45 Gy of radiation

- Patients are not required to have measurable disease; post-operative patients (patients who have had surgical resection of lung cancer) are eligible

- Patients must have pulmonary function as defined below:

- * Abnormal pulmonary function test within 3 months of study entry

- * Prior radiation to the lungs

- * Prior surgical resection of lung tissue (i.e. wedge resection, lobectomy, or pneumonectomy)

- * Clinical diagnosis of chronic obstructive pulmonary disease (COPD) or emphysema

- * Ongoing oxygen use

- There are no limits on prior therapy; patients are allowed to have prior chemotherapy, radiation therapy, and surgery; patients are allowed to have concurrent chemotherapy with radiation treatment; patients are allowed to have chemotherapy after radiation treatment; patients are not allowed to have planned lung resection after radiation

- Ability to understand and the willingness to sign a written informed consent document

- Patients will typically be enrolled on this trial prior to beginning the radiation treatment course; however, if a patient has had a SPECT/CT 99mTc-MAA and 99mTc-DTPA scan as part of routine medical care within 6 weeks prior to initiation of radiation treatment, he/she is eligible for trial enrollment up to the last day of the radiation treatment course

Other eligibility criteria may apply.

Exclusions (conditions that would prevent participation in this study)

- Patients must not be planned for lung resection after radiation therapy

- Patients receiving < 45 Gy radiation

- Patients who received radiation to the chest within the past 6 months

- Patients unable to tolerate a SPECT/CT 99mTc-MAA and 99mTc-DTPA scan

- Patients who are not planning to adhere to the required follow up schedule as outlined in this protocol

- Pregnant women

- Women of childbearing potential and men who are sexually active and not willing/able to use medically acceptable forms of contraception

- Patients unable to provide informed consent

Other exclusion criteria may apply.



Research Study Number       8180
    
Contact       Jennifer Revall, BA
    
Telephone       206/667-8629
    
   

Keywords
Lung Cancer; Solid Tumors

Disclaimer: We update this information regularly. However, what you read today may not be completely up to date.

Please remember:

  • Talk to your health care providers first before making decisions about your health care.
  • Whether you are eligible for a research study depends on many things. There are specific requirements to be in research studies. These requirements are different for each study.

Subscribe to an RSS feed of all trials

Fred Hutchinson Cancer Research Center is a world leader in research to prevent, detect and treat cancer and other life-threatening diseases.